Innovalve develops catheter-based heart valve therapies to treat patients with valvular heart disease. Their technology aims to improve patient outcomes by providing less invasive options for valve replacement and repair.
Funding
$10.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with valvular heart disease often require invasive surgical procedures for valve replacement or repair, leading to extended recovery times and potential complications. Current treatment options may not be suitable for all patients, particularly those who are elderly or have other comorbidities.
Solution
Innovalve is developing catheter-based heart valve therapies designed to offer a less invasive alternative to traditional open-heart surgery for patients with valvular heart disease. Their approach focuses on delivering and deploying heart valve replacements or repair devices through a catheter, minimizing trauma to the patient. By utilizing a catheter-based system, Innovalve aims to reduce recovery times, lower the risk of complications, and expand treatment options for a broader range of patients who may not be candidates for conventional surgery. This technology seeks to improve patient outcomes and quality of life by providing a safer and more effective solution for valvular heart disease.
Target Audience
The primary target audience includes patients with valvular heart disease who are seeking less invasive treatment options, as well as cardiologists and cardiac surgeons looking for advanced technologies to improve patient care.
Features
- Catheter-based delivery system for minimally invasive valve replacement or repair.
- Designed to reduce recovery time and complications compared to open-heart surgery.
- Intended for a broader range of patients, including those with comorbidities.